ClinicalTrials.gg
RecruitingNCT05046080Updated Aug 10, 2026

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix

An observational study in Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by M.D. Anderson Cancer Center · Observational

How we know

From the registry’s dates

  • Started Aug 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
70
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Adenocarcinoma, Clear Cell with a site in United States — 6 open to participants now, 13 under way, 2 of them phase 3. Adenocarcinoma, Clear Cell · United States.

Started
2021
with 1 other
Observational
Only one
of the 36
Primary completion
2026-09
later than 4 of 12 live
Registered
31st of 36
by date
Lead sponsor
3 of 36
M.D. Anderson Cancer Center

Among the 36 studies in Adenocarcinoma, Clear Cell with a site in United States, this one is one of 2 that started in 2021, is the only observational one, reaches primary completion later than 4 of the 12 other live ones, and was the 31st registered.

Adenocarcinoma, Clear Cell

46 studies on the registry are indexed under Adenocarcinoma, Clear Cell; 8 are open to participants now.

Browse Adenocarcinoma, Clear Cell studies →

Open to participants now

6 of the 36 studies in Adenocarcinoma, Clear Cell with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Adenocarcinoma, Clear Cell studies recruiting now, 8 set no upper age limit and none stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Adenocarcinoma, Clear Cell with a site in United States, or all of them as a file.
02

Study summary

This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. This study may help researchers learn more about the molecular profile of cervical clear cell carcinoma.

Read the detailed description

PRIMARY OBJECTIVE:

I. To perform a retrospective clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervix at M D Anderson Cancer Center (MDACC) and to delineate the immunohistochemical and molecular profile of these cases.

OUTLINE:

Patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.

03

Conditions studied

  • Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with clear cell carcinoma of the cervix, from January 1, 1985 to July 1, 2020

Eligibility criteria

Inclusion Criteria:

  • Patients diagnosed with clear cell carcinoma of the cervix at MDACC
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
70 participants (estimated)

Groups and cohorts

  • Observational (medical record review)

    Patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.

    Other: Electronic Health Record Review · Other: Laboratory Biomarker Analysis

Interventions

  • OtherElectronic Health Record Review

    Medical records reviewed

  • OtherLaboratory Biomarker Analysis

    Correlative studies

06

What researchers measure

Primary outcomes

  1. Clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervix

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2021 (actual). Primary completion is estimated for Sep 2026, 61 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2021
First posted
Sep 16, 2021
StartActual
Aug 6, 2021
Primary completionEst.
Sep 29, 2026
CompletionEst.
Sep 29, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05046080
Responsible party
Sponsor
First posted
Sep 16, 2021
Start date
Aug 6, 2021
Primary completion
Sep 29, 2026 (estimated)
Completion
Sep 29, 2026 (estimated)
Last update
Aug 10, 2026

Study contacts

Anasis Malpica
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion